<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770483</url>
  </required_header>
  <id_info>
    <org_study_id>SIMS</org_study_id>
    <nct_id>NCT01770483</nct_id>
  </id_info>
  <brief_title>The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients</brief_title>
  <acronym>HEP-C-FM</acronym>
  <official_title>The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Services Institute of Medical Sciences, Pakistan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Getz Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Services Institute of Medical Sciences, Pakistan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if nitazoxanide used in combination with
      interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic
      patients by improving their sustained viral response by more than 80%.Considering that the
      study is being conducted in a third world country like Pakistan, the standard treatment of
      hepatitis C is not cost effective. The aim is to introduce a new treatment comparable in
      efficacy to peginterferon and also cost effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After taking proper informed consent from patients, patients who fulfill the research
      criteria are randomized into 2 groups (control/study). Patients in both groups will be
      treated with conventional interferon alfa and Ribavirin.Those in study group will be given
      tab nitazoxanide 500mg twice daily in addition to conventional treatment. The patients will
      be followed up at regular intervals: 0,4,12,24,48 week.At each visit Hepatitis C
      Virus(PCR)RNA, Liver function tests, complete blood count will be done.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral Response,</measure>
    <time_frame>48 WEEK</time_frame>
    <description>Sustained viral response ,is negative Hepatitis C Virus(PCR)RNA test six months after end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of Alanine Transferase Test</measure>
    <time_frame>48week</time_frame>
    <description>Liver function test,showing resolution of the inflammation of liver parenchyma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>DIABETES MELLITUS Type 2</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitazoxanide</intervention_name>
    <description>nitazoxanide 500mg twice daily</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>tablet nizonide500mg</other_name>
    <other_name>tablet atizox500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional interferon alfa</intervention_name>
    <description>Inj interferon 3 Million International Units thrice weekly</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Inj uniferon 3 Million International Units</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>ribazole</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Ribavirin 400mg-1200mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatitis C genotype 3a

          -  Hepatitis C Virus(PCR)RNA Detected

          -  Alanine transaminase &gt;60

          -  Diabetic HbA1c&lt;8

          -  BMI&gt;23

        Exclusion Criteria:

          -  Previously treated Hepatitis C patients

          -  Pregnant females

          -  Decompensated liver disease,Child class B OR above

          -  Thyroid disease,Thyroid stimulating hormone&gt;10,0.05

          -  Absolute neutrophil count&lt;1500,Platelets&lt;80,000,Hb&lt;10g Female,&lt;11g Male

          -  Severe cardiac disease,New York Heart Association2

          -  Moderate to severe depression assessed by Beck Depression Inventory scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FAISAL MASUD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Principal SIMS/Services hospital lahore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AMENA MIRZA, MRCP,FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior registrar ,Services hospital lahore/SIMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madiha Fida, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>House Officer Services Hospital Lahore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endocrinology and Diabetes management centre</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2013</study_first_posted>
  <results_first_submitted>March 7, 2013</results_first_submitted>
  <results_first_submitted_qc>March 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2013</results_first_posted>
  <last_update_submitted>September 15, 2013</last_update_submitted>
  <last_update_submitted_qc>September 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Services Institute of Medical Sciences, Pakistan</investigator_affiliation>
    <investigator_full_name>Prof. Faisal Masud</investigator_full_name>
    <investigator_title>Principal SIMS</investigator_title>
  </responsible_party>
  <keyword>Nitazoxanide,</keyword>
  <keyword>Sustained viral response</keyword>
  <keyword>Type 2 DIABETICS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Data was collected from diabetic patients coming to diabetes management center Services Hospital Lahore. Recruitment started on july 2011 and last patient was recruited in March 2012.</recruitment_details>
      <pre_assignment_details>Initially 153 patients were recruited but only 66 patients were enrolled in the trial based on our inclusion criteria. Following patients were excluded:
33 because of HCV genotype other than 3
18 because of normal ALT
9 with undetectable HCV PCR
2 because of thyroid dysfunction
25 were lost to follow up</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
        </group>
        <group group_id="P2">
          <title>Study Group</title>
          <description>Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
nitazoxanide : nitazoxanide 500mg twice daily
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
        </group>
        <group group_id="B2">
          <title>Study Group</title>
          <description>Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
nitazoxanide : nitazoxanide 500mg twice daily
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.30" spread="6.07"/>
                    <measurement group_id="B2" value="47.21" spread="5.464"/>
                    <measurement group_id="B3" value="47.26" spread="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pakistan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Viral Response,</title>
        <description>Sustained viral response ,is negative Hepatitis C Virus(PCR)RNA test six months after end of treatment.</description>
        <time_frame>48 WEEK</time_frame>
        <population>Sample size has been calculated using Epi-Info 3.5.1 with the following assumptions.
Reported ETR with Interferon + Ribavarin = 44 % Expected ETR with Interferon + Ribavarin + Nitazoxanide = 80 % Confidence Level = 95 % Power of Study = 80% Calculated Sample Size = 66 i.e. 33 in each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
nitazoxanide : nitazoxanide 500mg twice daily
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Viral Response,</title>
          <description>Sustained viral response ,is negative Hepatitis C Virus(PCR)RNA test six months after end of treatment.</description>
          <population>Sample size has been calculated using Epi-Info 3.5.1 with the following assumptions.
Reported ETR with Interferon + Ribavarin = 44 % Expected ETR with Interferon + Ribavarin + Nitazoxanide = 80 % Confidence Level = 95 % Power of Study = 80% Calculated Sample Size = 66 i.e. 33 in each group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalization of Alanine Transferase Test</title>
        <description>Liver function test,showing resolution of the inflammation of liver parenchyma</description>
        <time_frame>48week</time_frame>
        <population>Sample size has been calculated using Epi-Info 3.5.1 with the following assumptions.
Reported ETR with Interferon + Ribavarin = 44 % Expected ETR with Interferon + Ribavarin + Nitazoxanide = 80 % Confidence Level = 95 % Power of Study = 80% Calculated Sample Size = 66 i.e. 33 in each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
nitazoxanide : nitazoxanide 500mg twice daily
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Normalization of Alanine Transferase Test</title>
          <description>Liver function test,showing resolution of the inflammation of liver parenchyma</description>
          <population>Sample size has been calculated using Epi-Info 3.5.1 with the following assumptions.
Reported ETR with Interferon + Ribavarin = 44 % Expected ETR with Interferon + Ribavarin + Nitazoxanide = 80 % Confidence Level = 95 % Power of Study = 80% Calculated Sample Size = 66 i.e. 33 in each group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
        </group>
        <group group_id="E2">
          <title>Study Group</title>
          <description>Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
Ribavirin : ribazole
nitazoxanide : nitazoxanide 500mg twice daily
conventional interferon alfa : Inj interferon 3 Million International Units thrice weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="33"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dry Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Faisal Masud</name_or_title>
      <organization>SIMS</organization>
      <phone>00923004260213</phone>
      <email>faisalmasud@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

